talked about the oil companies kerch like it. >> kafrp cbs i like it here even though up a little bit. >> beakers. >> tlt oil down less reason to raise lates. >> dan. >> xle tradedrates >> "mad money" with jim cramer starts right now my mission is simple -- to make you money i'm here to level the playing field for all investors. there's always a bull market somewhere, and i promise to help you find it. "mad money" starts now hey, i'm cramer. welcome to "mad money. welcome to cramerica other people want to make friends, i'm just trying to save you money. my job is not just to entertain but teach you. so call me at 1-800-743-cnbc or tweet me @jimcramer. what eat cleesh cle what's better for our

economy? why choose today, we got both, a one-two punch that sent the bears reeling. which is why the dow surged 265 points, the s&p 500 ran up, and the nasdaq jumped 1.75%. ♪ hallelujah >> after two days in a row, the kodiaks and grizzlies were ready to pounce, but thanks to the chinese thaw, the bulls racked up another win of course, tomorrow is another day. because i'm mindful that apple reported numbers tonight that came with a forecast that some regarded as disappointing along with news they're not going to break down what certain products are selling well or selling poorly and you know what? i think there are a lot of people who wanted to guide up and didn't want to hear about this information and you know what? they're not going to do that for the sake of doing so

so the numbers might cause a pause in the tech rally tomorrow probably catch some downgrades of apple but let's not get too granular about apple, you know what these are volatile times think about what happened if you panicked last thursday let me walk you through what happened today and why it could prolong the rally. i've been telling you for weeks and weeks, we're in an environment where bad news is good news. i mean anything that suggests the fed's eight rate hikes are doing their job, slowing the economy to the point where the fed can tone down the rhetoric, and how they're willing to take rates too high in order to break what i would call as nascent inflation. at 10:00 this morning, we got the bad news we had been hoping for, something that confirms everything i've heard from the companies i talked with. i'm talking about the supply management purchasing manager's

index, which gave us a reason to suggest there is a real slowdown and that it started taking hold in october like i've been telling you. the pmi came in at 57.7, wall street was looking for 59. new orders index plunged to 57.4 last month the production index sank from 64.9 to 59.9 even the employment index flip to 56.8. i know these are all just seemingly numbers on a black board, but what i've been looking for is a recognition by anybody that we've seen some real deterioration the fed has to wake up and look how the economy is down shifting tomorrow is the employment number i'm looking at things at like american electrical power told us already last night, that things are slowing gigantic coverage area i'm not saying they need to stop that immediately i'm fine with another rate hike

next month it's like the fed, the ism purchases index jumped from 66 to 71. that's too hot however, think about it. the price of oil has plummeted, the price of wood has come down, all the metals most commodities are headed lower, not up. the lower prices will work their way through the system in a positive way, which means the inflation problem will solve itself that's good news it explains half of the rally. remember, weaker data gives jerome powell some wiggle room to pause for three rate hikes next year which could hurt the economy. a little bad news, but let's say we get it now. as positive as pmi was for the broader market, president trump's stunning tweet changed the complexion of the entire nasdaq which had just begun to

start swinging again after two good days. let me read it to you. just had a long and very good conversation with president xi jinping of china we talked about many subjects with a heavy emphasis on trade those discussions are moving along nicely with meetings being discussed in argentina wouza! we had a remarkable selloff in tech, and the place where the nuclear bomb went off was in the semi conductors. that's where things were really, really bad why? because not only has business slowed and the trade war hurt the group, but chip makers that might otherwise be able to rally have been held back because there's been a real derth of takeovers. you know what? talk about timing. there was so much irony here

turns out the linkage cut positive for mxp, between the president's tweet and earnings, the stock market went up same goes for the numbers for the chip maker, what a turn. naturally, the positive action spread right through the whole group. the philadelphia semi conductor index, right after the president's tweet, it rallied 4.6% big standout, micron, the commodity chip maker with stocks that had lost 40% of its value going into today's session the stock finally rallied. it helped as the president's tweeting, of course, the justice department indicted the chinese

firm they've been stealing micron's trade secrets. and we saw a nice run in stocks from nike, casino operators, wynn resorts and tonight we got a stellar set of numbers from starbucks, which called out china as the fastest growing market all right. we've got to come full circle. i'm sure people are saying jim, i don't care about any of that, what matters is apple reported numbers they didn't like and the stock got thrown away because they will no longer give you a breakdown of individual product. i'm sure there are people who will say, you know what? i have to panic and sell apple, because apple must be turning down, and it's going to be herd animals all over the place, and all i can tell you is wait a second, please, just wait a second apple, apple's ecosystem continues to grow. the stock was up 30% going into the session. i accept that the stock is going

to go lower. but remember, we just had 1,000 dow points that worth capturing, even if we get what i'm regarding as an undeserved, crushing of the stock of apple tomorrow you know what i have to say a stock up 30% coming in, that reported an amazing number, but was conservative and changed the way it's breaking things down, here's what i say -- i would still own it i wouldn't trade it. bottom line, we need to see the fed or the president blink in their respective battles against inflation in china neither blinked today. but we got a sense of how things could go right and it sent stocks flying. and if they blink for real, even if apple is the worst stock in the world, we could have more upside but after this remarkable run, indeed, let's not get too greedy

gary in alabama, gary. >> caller: hey, jim, thanks. big boo-yah from south alabama >> nice to have you. >> caller: love your show. thanks for helping me fund my retireme retirement >> that's good, man. that's what i want >> caller: red hat trading today around 172 i want to know if it makes sense to hold on to it >> i thought about that all day today. then i'm doing a talk for members of the action alerts club, i said hey, you know what? it's got to close with pfizer. i crushed myself so i'm going to say we don't need to be there it's just too hard all right, guys, today we saw what happens when you get a thaw with china and data of a slowing economy. now, aren't you happy you didn't panic from last week of course, tomorrow is a new day, and everyone has decided apple's best days are behind it.

if you can't take the pain, go ahead and sell me, i think the best days are still to come. on "mad money" tonight, a sector that was once the safe haven on wall street is now the most broken i've ever seen. and a little drug stock, recent fda approval is a crucial moment in the history of cannabis medical cannabis so what is ahead i'm sitting down with the ceo to find out you're going to want to hear this, because those stocks are not so bad and cyber security has been on the decline, is microsoft taking their market away? i'm going to find out what's going on there stick with cramer. >> don't miss a second of "mad money. follow @jim cramer have a question? #madtweets send jim an e-mail to madmoney@cnbc.com. ivus cl alat 1-800-743-cnbc miss something head to madmoney.cnbc.com.

- i love my grandma. - anncr: as you grow older, your brain naturally begins to change which may cause trouble with recall. - learning from him is great... when i can keep up! - dad's got all the answers. - anncr: prevagen is now the number-one-selling brain health supplement in drug stores nationwide. - she outsmarts me every single time. - checkmate! you wanna play again? - anncr: prevagen. healthier brain. better life.

i am a techie dad.n. i believe the best technology should feel effortless. like magic. at comcast, it's my job to develop, apps and tools that simplify your experience. my name is mike, i'm in product development at comcast. we're working to make things simple, easy and awesome. ♪ in a big decline when stocks

fly like they did once again today, we've got to talk about what counts as safety to upgrade our portfolios during the meltown, a lot of companies saw their stocks go down and down some more. the drug stocks have long been viewed as a bastion of reliability. but lately a number of big pharma names have been annihilat annihilated, which is highly unusual. aren't these great companies it's a good time to talk about the unkars richaracteristic beh. the stocks are selling like donna summer, because when they're bad, they're so, so bad. all allergen, when they caught a takeover bid from pfizer, i decided not to ring the register and i rode it down 50% before

dumping my position. i didn't like the company was losing exclusivity after my trust look a loss, what happened the stock rallied furiously. but this week, the stock came plunging back to earth until today. what happened? they reported a quarter that on the surface looked impressive. while almost every analyst in the quarter, we started hearing talks the ceo wasn't bringing out enough value quickly enough and the stocks got obliterated if you bought them when it was dumping up, it lost 20 points in the blink of an eye. they do have two huge drugs in the pipeline, for migraines and treatment for depression but their competitors at amgen has a new migraine drug that has

a new drug that is now the standard of care i think the stock is way too low versus where it was trading a couple of weeks s ago. alergen, the stock rebounded 4% today, but be careful. for months now, we've been hearing about upcoming drugs that's correct rival the blockbuster anti-inflammatory drug here in america, york may be a different story. i thought everybody knew about this stuff this is a new thing with drug stocks everybody has to know, right i figured it was baked in when it was 100 i mean, this was touching 70-ish it was like it was a whole new batch of uninformed shareholders

buying the stock for the first time today but it's hard to see this stock crumble in a selloff a few years ago, gilead made a fortune, but when you cure a disease, you start running out of customers now they're introducing a generic version of the drug. while the stock bounced today, i can't see it turning around long-term. bristol myers has been left in the dirt by merck. yesterday out of nowhere, baxter international has been hit with market share losses. stock lost 10% in a single day where is the safety here these stocks, like the food brothers, they used to be safety first situations no longer, they're safety last

these names are bouncing today the next time the market gets slammed, you don't want to rely on a broken food stock protect your portfolio rent in rhode island, kent >> caller: good evening, how are you? >> good. how about you? >> caller: doing great your take on cvs health. they're in the final stages of the acquisition with aetna quarterly mornings come out monday morning >> i like this situation very much sir, i like it i'm a buyer of cvs by the way, remember how much we loved cigma and everybody laughed at us? they said come on, jim cigma is now up 35 points. i think cvs is in a good situation. let's go to michael in illinois, michael. >> caller: hey, jim, what's up >> a $2 trillion mark cap,

people are saying you're cursed. i don't know about that. >> caller: i just wanted to say thanks for having me on the show i'm an air force vet who has a daughter who is active daughter. >> thank you for serving >> caller: thank you so much i wanted your take on a company called acorn pharmaceuticals we know about the failed buyout -- >> generic we're going to pass. we have stocks like merck that are winning, and the drug stocks that are doing badly, they don't just stop doing badly, sir so if it's doing badly now, it's going to do badly to the year end. and our veterans show is november 12th, and it's always one of the highlights of the year even when they used to believe safe havens for the drug stocks, we have to be careful. but when they're bad, they are so, so bad

tonight, the fda approved a medication now available in the u.s. what does that mean for the company? i'm going one on one with the ceo. and is there a new reality and i'm taking a close look at the health of the american consume we are the ceo of a company. so stick with cramer illumination! today we will steal christmas, in style. but let's start by finding some reindeer. we've hit the motherload. oh, hey there. [ screaming ] [ bahh ] [ sigh ]

well, santa had eight. he looks like he ate the other seven. the grinch. rated pg. fred? what are you doing? okay.

we spent a lot of time lately talking about the

medicinal marijuana business but there's an actual drug company that's been studying cannabis for years in order to create real medication, and the stock was up $10 today or 7% on news their lead drug is now available here in the u.s. make no mistake, gw pharmaceuticals is not a me discadi -- not a medicinal marijuana play today, the company released their epilepsy drug here in america, and they have another one for multiple sclerosis spasms but the stock lost 20% of its value last month it's not like you're chasing it. don't take my word for it. let's check in with the ceo of

gw pharmaceuticals welcome back to "mad money." >> thank you for having me back. >> when i speak to doctors, sir, the first thing they say is what kind of medicine can we prescribe where it may be 5% this or 10% that, we don't know what it's in it. we need an actual fda pill that's regulated so we know what the dose is, that's what gw pharma is offering, right? >> that's what we've been working on for 20 years now. and this year has been an extraordinary experience, a series of historic milestones that the fda has approved the medication, the dea has reclassified it, and today we're relaunching it in the united states >> can you tell people about the tortured way that you've had to get this because the kid, the people who are going to be taking that pill are people that really have their lives dramatically changed by you >> well, the response of each

patient will vary, but the evidence that we have generated in these two very difficult forms of childhood epilepsy has shown for this product to reduce seizures in a material way in a number of these children so we're hopeful that this medication can make a meaningful difference to many patient's lives across the country >> were you surprised that the dea, this dea realized how important this is and changed class one to class five? >> well, i think what this reflects is an understanding within the dea and fda and other circles of federal government, when you do real science, you produce data that provides evidence of safety and efficacy and you manufacture product where you know exactly what is in it day in, and day out. that these agencies pay attention to this. they understand there's a need, they understand that they can met that unmet need. and i'm not surprised actually that they've decided to

recommend approval of the drug and to rechas fie lassify it it talks to science and to addressing a real patient need >> do you think people understand, sir, that you have a dosage that you're just like every major drug company instead of just getting mail order from wherever, from a state that it's legal or you go to oregon or california and bring back something and take it, do people understand the difference, sir >> i think there is still a need for education out there, but there is a real difference between an fda approved medication and anything else that's a standard that the fda hold we spent years to meet that standard, and have now done so we believe that physicians are desperately needed, a treatment option which they know can have the reassurance of fda approval and believe this is going to be an important new opportunity for patients to see the benefits at

last of an fda approved option >> so you've spent a fortune to get this through and use a huge amount of science. what other applications will we be able to see for this, because it's such an important new drug? >> well, first and foremost, we will continue to speak new indications within the field of epilep epilepsy as you mentioned in your introducti introduction, we have a product outside of the united states, and we believe there is potential to bring that product into the united states over the next few years and beyond that, we believe that the potential for canavanoids, approval is real, and we're leaders in the world in this area, and believe that this journey is now at its beginning if the united states to bring this medication to patients that meet fda requirements. >> how are you going to be able to prevent off label use from

doctors who say, i'll give this to you because it does happen to be one of the great painkillers, it does happen to do so many wonderful things for people who have post traumatic stress, how do you make it so they don't use it, even though frankly, sir, it would be good? >> well, that's certainly not for me to say. i can reassure you that our company is committed to only marketing this medication for its approved uses. physicians do have discretion as to how they prescribe it we believe it is appropriate for this medication to be provided to whom it is indicated. >> are there doctors who have been reluctant to give people different cannabis treatments, knowing it could be anything that's inside it, and really just want something that is actually a dose? >> there's been a huge need, and we heard voices from the medical community, for several years, that they need to have access to medications where they have the

assurance of standardization, they know what is in it, they understand the dosing, they understand its safety profiles and interactions and which patients to use it but we believe the product responds absolutely to that need, and that our future products can similarly respond to needs in other parts of the medical community. >> do the majority of congress people, are they willing to go with this, or did it not matter? >> science has head the way here opposed to legislators or politics i think that's exactly the right way it should be within the field of medicine. >> how many other studies do you have going on right now? >> we have phase two studies going on in a range of compounds, looking at conditions such as autism and psychiatric disease. we have data already in the field of multiple sclerosis and pain we have research and oncology and earlier stage research in other areas. so there really is a great deal for us to continue to research in over the years ahead.

>> one last question, do you think there are companies in canada being irresponsible by saying it's medicinal? >> it's important to distinguish between what is medicine and what is not. the fda make that determination, and where there are products that don't meet fda standards, we don't believe that they should be appropriately termed as medication. >> i want to congratulate you for what you have done, this is a compassionate use drug you worked hard and got it done and you've done a great job for shareholders >> thank you, jim. >> that the ceo of g w pharmaceuticals. this is a real company with the kind of science you need if you're going to go after these tough illnesses. "mad money" is back after the break.

the nature of a virus is to change. move. mutate.

today, life-changing technology from abbott is helping hunt them down at their source.

because the faster we can identify new viruses, the faster we can get to stopping them. the most personal technology, is technology with the power to change your life. life. to the fullest.

now that the dust seems to have settled, i think it's worth circling back to some of the companies that had the misfortune of reporting when everyone was reporting here's a stock that's been getting slammed since the summer the actual numbers look good to me 12% earnings, higher than expected revenue but some analysts were disappointed by the guidance of next year. at the same time, two of the top executives of corporate development announced their resignations, boy could be a worrisome sign in short, to many it wasn't a perfect quarter, but it wasn't a quarter that should have caused a 15% decline. so is it a broken stop or

something that we should worry about? let's take a look more closely with the ceo welcome back to "mad money." >> good to see you >> we talk about the endless customers, because we are dealing with malicious, weaponized documents now, so it sounds like the opponents are only just getting stronger >> absolutely. it's one of the key reasons we've been growing at the rate we've been growing the threat landscape continues to get more complicated, and the fact that more organizations are moving to the cloud. >> i don't think of tech companies having difficulty finding the right people but you -- maybe it's a high quality problem, but you are having trouble getting all the sales people you want. >> one of the exciting driver growths is international part of that is getting great sales people on board, and we were slower than we hoped. and that's something that is easily turned around

if you look at it at a higher level, over 80% of the revenue comes from domestic markets. that opportunity outside is phenomenal so we're excited about the opportunity, and we're confident that we can improve our execution. >> i have to ask you about the coo. he came in, in july and he thought that there could be a succession why? >> i am going to be ceo for years and years, but the flip side, we worked on a succession process. he had the opportunity to succeed me in the short term i'm going nowhere. i'm thrilled to be at the company, and we have a greater opportunity today than ever before so super excited and glad to be part of it >> the beginning of the teleconference call, he says listen, this is going to be our bailey wick. we're going to be security he got a whole new system that's easy to go to, where it offers a

lot of services. you talk about windows and how people at windows needs you. are they catching up and making it so it's more difficult to do this >> we talked about the fact that microsoft is a critical catalyst for us customers want world class security focused on these specific malicious issues, and we feel like we're providing a great product for the customers and security obviously is a primary concern. and we noted in our prepared remarks, we had the best quarter, moving customers over from microsoft capabilities to the solutions. so we feel like we're helping microsoft and giving customers a world class experience >> there is often a belief that it's all zero sum. these are all partners of yours. >> that's right. one of the investments we made is doing technical integration,

across the ecosystem where we think those shuolutions will be installed. by doing integration for our customers, they don't have to make it all work together, we'll do that for them >> when will people get serious, because you have a hack, and there's going to be some personal stuff that people get hurt on. but the s.e.c. is getting serious now, aren't they >> the s.e.c. came out with a set of recommendations regarding the challenges people are experiencing around phishing, malicious e-mail, fraud. so they basically warned people to look at their processes and security posture we think this is an important notification and catalyst for the business for us. >> so they are people calling you in saying okay, look, we need a consultation, tell us what to do because i think everyone is pretty overwhelmed >> it's pretty complicated today. the threat landscape continues to shift we see different forms of

attacks, so having a strong security posture is something that every company has to do >> one last thing. analysts at proof point, raising a yellow flag after recent checks too many issues to defend. what is -- what are the too many issues to defend yes, the departure, but i thought -- i didn't see a lot of issues >> we had a great quarter. >> i know. >> deutsche bank downgraded us, but we don't pay attention to the day-to-day movement of the stock market we're super excited, because the threat landscape is there. >> you should be super excited that's gary steele, ceo of proof point. "mad money" is back after the break.

at&t provides edge-to-edge intelligence, covering virtually every part of your healthcare business. so that if she has a heart problem & the staff needs to know, they wilspecialists yeah, i'm looking at them now. & they'll drop everything hey. & take care of this baby yeah, that procedure seems right. & that one too. at&t provides edge to edge intelligence. it can do so much for your business, the list goes on and on. that's the power of &. & when your patient's tests come back...

it is time it's time for the lightning round. [ indiscernible

and then the lightning round is over are you ready, skedaddy. bob in california, bob >> caller: hey, jim, my question is about biogen, specifically your opinion on the new board management team. >> i like the management team, i don't like the hype involving the drug for alzheimer's puts too much pressure on the stock. tony in new york, tony >> caller: hello, mr. cramer, first-time caller. my stock is -- >> i think it's a safe yield that's the tide you're swimming against. richard in connecticut, richard. >> caller: boo-yah, cramer, first-time caller, long-time listener >> this is ridiculous at this point that this stock is down. reminds me of idti

let's go to jack in ohio, jack >> caller: love your show, jim thanks for your help >> thank you, jack >> caller: it's right above a 52-week low and right under a 3% yield, which is pretty good. and i love their product colga colgate. >> they did not have a good quarter, but i'm going to wait 3.5% is where i would buy this and not before then. so we've got to go with the good ones, not the ones that are out of favor matt in virginia, matt >> caller: jim, my man i want to give you a big red cornhusker boo-yah >> remember the cornhuskers. they were the power house. what's going on? >> caller: it will happen again. my question is, what are your thoughts on carizo >> boy, i tell you, i think chip

johnson has done remarkable work there and he's expanded at the right time the group does not want to go higher, because oil is plummeting steve in new york, steve >> hey, jim, i want to ask you about a company that has a $32 billion market cap they announced earnings last night. they announced a $3 billion dollar share buyback, which is following a $2 billion buyback, and raised their dividend 24% in february of this year. the company is allstate. >> they did miss the quarter really badly you can't touch it, can't touch it let's go to don in missouri, don. >> caller: hey, jim. just wanted to thank you for all you do to help us be better investors. >> thank you very much >> caller: my stock is blackstone

>> i like blackstone very much i recommend it, and the ceo does a very good job. i need to go to amy in maryland, amy. >> caller: there are many online dating sites what do you think of the match group, mtch? >> i care more about the stock than the actual implementation of the dating. i think she's asking more about the stock, right, regina yeah, because the stock -- i don't know the service, but the stock is really inexpensive and it's doing a remarkable job, and i'm a buyer of the stock, of the stock! of the stock let's go to -- of the stock! len in new york, len >> caller: hi, jim, thank you for the excitement my question today is about ubnt. >> you know what if we're going to do wireless network, high performance

radios, there's so many others i would rather have you be in. that is way too controversial for me and that, lamg, dies and gentlen is the conclusion of the lightning round. >> the lightning round is >> the lightning round is sponsored by td ameritrade the time from sunset to sunrise. right. but you can trade... from, from... from darkness to light.

♪ central dilemma of this market, the shopping -- with properties

in the northeast and mid-atlantic, and they're beautiful. last night, they reported a darn good quarter, a nice top and bottom line. in fact, this morning's conference call, the ceo described it as the best quarter we've ever had, and what happened the stock barely bu lly budged. the reits are just less attractive that's not much higher of a yield than owning risk free treasuries and a lot of people are concerned about fed mandated slowdown, so when can investors get excited again? let's begin with the president and ceo of federal realty trust, who know more about the quarter and what lies ahead for one of the largest land lords in america. welcome back to "mad money." all right. greatest quarter ever. how does that translate to someone who says, i love that

guy, but i'm getting that 3.5% on my five-year. >> let's talk about what it means first of all when i say the best quarter we've ever had, reitz are measured, $1.58, we've never done that much cash flow in a 90-day period of time. it's the direction we're going i think we're the only shopping center reit that has increased cash flow every year since the recession back in 2009 or 2010 but it's that dividend question i wanted to address. >> sure. >> there's no question, yields are up on bonds. so as i sit and i look at federal 3.2 percentage yield on -- from a dividend perspective. you have to say, is that it? let me ask you this, and this number wloblew me away, there a 26 companies in terms of public

companies that have a record of increasing their dividend every year for 50 years or more. 5-0, 50 years. federal is one of them proctor and gamble, coca cola. those three are the only ones today that have a 3.2, 3.3 yield. so stop and say, this is a special reit it's not like most now let's go further with the stuff that we have done and have announced and some stuff that hasn't been announced, we have the ability or are highly likely to grow cash flow of 19 over 18 and 20 over 19. >> you have that level of visibility proctor does not and coca cola does not >> thanks, i appreciate that >> so when you think about that, it's hard for me to say that this is the same as a bond >> capital appreciation is important. if you were to liquidate this

company, sell every shopping center, we would effectively get significantly more than the to be is trading at today that should matter, too, from a bottom level >> absolutely. let's talk about things that have happened in your industry, that make you more confident than i've ever seen. one is, there's been a change in the mixed use that you put together it's no longer just a shopping center the second thing is, it's very clear to me that the omni channel, brick and mortar side may be an advantage versus the -- >> it's really interesting in terms of what's changing in the marketplace and how the consumer is growing or adapting, whatever when we sit and think about our company, we basically -- our core competency is putting the right retail together in any particular location to create a place. those places are -- just in that first suburb at the center of the major cities along the east coast and california

but once we have them there, how about following the trend, which we've been doing for 20 years, 20, of saying you know what? people are sick of traffic people are looking to efficiency and things like that they want to live, they want to work, they want to have their lives at these environments. >> so if i'm working at spunk, i want to have -- >> why spunk this >> because they're one of my favorite companies they're a brilliant company, incredibly well run. if i worked there, i would like to have this at my convenience, rather than at my home >> as a result, we now have completed two buildings, office buildings, in our retail based company for spunk. and that's in silicon valley at our santana row community. i've got to tell you, you can -- with what we hear from their employees, with how we see them

using the entire property, the office and the residential are integral -- >> how about the fact that you already know that every time somebody -- what happens to the bankruptcy, i see it's very clear that any opening, you're renting at a higher price than last year. >> that's right. again, if you're in the right locations, demamd exceeding supply is not the case in our industry can i hit on one thing there's a lot of online companies that just self-years ago would say we don't need brick and mortars. we're online, it's more efficient, et cetera but the cost of acquiring a customer is a hard thing to do, and how to deliver goods is not all figured out yet. there are dozens and dozens, and maybe hundreds of not even start-up anymore, but

established online companies that are saying, bricks and mortar is a critical part of what we do >> one last question, i don't like a fed that says maybe we have to overshoot to slow down the economy. everything i hear from you is things are really good what's the matt we are that? can't we let it go or does the fed have to slow it? >> i've got to pick the things i can control and the things i can't. the glass half full part of this conversation is, you know, with interest rates rising, interest rates are only rising because the economy is doing well, consumers are doing well, and we're in a consumer business so from my perspective, that balance and how that works is above my pay grade but i've got to tell you, things look pretty good >> we just got starbucks numbers tonight. >> definite important tenant it's part of how you want to hiv going forward. >> i want to thank don wood for

putting it in perspective. president and ceo of federal real estate. "mad money" is back after the break.

apple's down for two reasons. they're not going to break down to give you numbers of different divisions they have. i think the latter doesn't interest me at all the company is historically very conservative the actual numbers stand for them selves. they are very good the stock was up 30% going in today. i think most of the other tech stocks we know that reported were way down going in, so it was natural that it comes down you know what? this may be an opportunity especially if it goes under $200 for those who have never bought the stock, i would start nibbling the market the last three last dayshasn't been that welcoming i always like to say there's a bull market and i try to find it just for you here on "mad

money. i'm jim cramer and i'll see you tomorrow >> welcome to the shark tank, where entrepreneurs seeking an investment will face these sharks. if they hear a great idea, they'll invest their own money or fight each other for a deal. this is "shark tank." ♪ is a grown-up version of a childhood favorite. whoo! herjavec: cool. corcoran: wow. [ chuckles ] that just happened. sharks, my name is tyler hadzicki, my company is leaux racing trikes, and i'm here today seeking $120,000 in exchange for 20% of my company.